在学术医疗中心实施综合临床药物基因组学测试
Claire E Knezevic1, James M Stevenson2,3, Jonathan Merran2
1Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
The journal of applied laboratory medicine
|December 10, 2024
概括
通过实施内部的药物基因组学管道,通过减少周转时间和将结果集成到电子健康记录中,以更好地支持决策,改善了临床护理.
科学领域:
- 临床基因组学 临床基因组学
- 药物基因组学的实施方法
- 医疗信息学 医疗信息学
背景情况:
- 药物基因组学提供了诸如减少不良事件和节省成本等好处.
- 药物基因组学实施的关键障碍包括长时间的交付时间和EHR整合挑战.
- 开发了一种新的临床工作流程,以简化内部药理基因组学测试和EHR整合.
研究的目的:
- 开发和实施一个高效的药物基因组学测试管道.
- 将药物基因组学结果集成到电子健康记录 (EHR) 中,并提供临床决策支持.
- 评估实施的工作流对交付时间和临床效用的影响.
主要方法:
- 使用QuantStudio 12K Flex.开发并验证了一个11基因可操作的药物基因组学小组.
- 通过自定义的驱动器和规则引擎,将基结果,双型和代谢表型集成到EHR中.
- 整合了电子咨询 (eConsult) 服务,并监控可操作结果的频率和交付时间.
主要成果:
- 该小组涵盖了11个基因中的39个等位基因,提供双型和代谢表型.
- 临床面向的表型摘要 (基因组指标) 在EHR中提出.
- 平均周转时间为4.6天;22.1%的测试具有可操作的药物基因,其中67%涉及eConsults.
结论:
- 在一个学术医疗中心成功运行了一条内部药物基因组学管道.
- 药物基因组学的直接EHR整合结果增强了临床决策支持.
- 工作流程促进了在多个临床领域使用药物基因组学测试.
相关概念视频
Pharmacogenetics and Pharmacogenomics: Overview
158
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
158
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
116
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
116
Pharmacogenetics of Drug Metabolism: Overview
131
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
131
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
203
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
203
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
69
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
69
Pharmacogenomics: Identification of New Drug Targets
86
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
86


